INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 245 filers reported holding INTELLIA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,165,812 | -8.0% | 68,495 | +18.6% | 0.00% | 0.0% |
| Q2 2023 | $2,354,800 | -1.5% | 57,744 | -10.0% | 0.00% | 0.0% |
| Q1 2023 | $2,391,616 | +6.8% | 64,170 | +0.5% | 0.00% | 0.0% |
| Q4 2022 | $2,239,328 | -25.7% | 63,847 | +17.9% | 0.00% | -50.0% |
| Q3 2022 | $3,014,067 | +5.9% | 54,151 | -1.0% | 0.00% | 0.0% |
| Q2 2022 | $2,847,133 | -21.1% | 54,693 | +9.8% | 0.00% | 0.0% |
| Q1 2022 | $3,608,594 | -13.6% | 49,800 | +42.2% | 0.00% | -33.3% |
| Q4 2021 | $4,177,000 | -10.5% | 35,019 | +0.6% | 0.00% | -25.0% |
| Q3 2021 | $4,669,000 | -18.9% | 34,804 | -2.1% | 0.00% | -20.0% |
| Q2 2021 | $5,757,000 | +133.6% | 35,558 | +15.8% | 0.01% | +150.0% |
| Q1 2021 | $2,464,000 | +51.1% | 30,700 | +2.4% | 0.00% | 0.0% |
| Q4 2020 | $1,631,000 | +189.7% | 29,982 | +5.9% | 0.00% | +100.0% |
| Q3 2020 | $563,000 | +4.6% | 28,316 | +7.5% | 0.00% | 0.0% |
| Q2 2020 | $538,000 | +73.5% | 26,340 | +3.8% | 0.00% | – |
| Q1 2020 | $310,000 | -11.7% | 25,364 | +6.0% | 0.00% | – |
| Q4 2019 | $351,000 | +9.0% | 23,938 | -0.9% | 0.00% | – |
| Q3 2019 | $322,000 | -17.0% | 24,149 | +2.0% | 0.00% | – |
| Q2 2019 | $388,000 | +0.3% | 23,679 | +4.3% | 0.00% | – |
| Q1 2019 | $387,000 | +34.8% | 22,710 | +8.3% | 0.00% | – |
| Q4 2018 | $287,000 | -54.9% | 20,973 | -5.8% | 0.00% | -100.0% |
| Q3 2018 | $637,000 | -7.5% | 22,255 | -11.5% | 0.00% | 0.0% |
| Q2 2018 | $689,000 | +143.5% | 25,157 | +87.7% | 0.00% | – |
| Q1 2018 | $283,000 | +8.0% | 13,403 | -1.8% | 0.00% | – |
| Q4 2017 | $262,000 | -13.8% | 13,651 | +11.3% | 0.00% | – |
| Q3 2017 | $304,000 | +43.4% | 12,262 | -7.3% | 0.00% | – |
| Q2 2017 | $212,000 | +542.4% | 13,224 | +451.2% | 0.00% | – |
| Q1 2017 | $33,000 | +153.8% | 2,399 | +134.5% | 0.00% | – |
| Q4 2016 | $13,000 | -86.5% | 1,023 | -81.9% | 0.00% | – |
| Q3 2016 | $96,000 | -5.9% | 5,660 | +18.3% | 0.00% | – |
| Q2 2016 | $102,000 | – | 4,783 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |